|
|
Langues
|
|
|
Par thème
|
|
|
Par secteur d'activité
|
|
|
Par pays
|
|
|
|
NV387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. NYSE American:NNVC the "Company", a global leader in broadspectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10Q for the fiscal second quarter ending March 31, 2024 with the Sec... Lire le communiqué |
|
| |
|
| |
|
|
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. NYSE Amer.:NNVC the "Company", a global leader in broadspectrum antiviral nanomedicines, says that antiviral activity of NV387 against RSV/A2 is strong enough to have resulted in full surviva... Lire le communiqué |
|
| |
|
| |
|
|
NV387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 8, 2024 / NanoViricides, Inc. NYSE American:NNVC the "Company", a global leader in broadspectrum antiviral nanomedicines, says that the ultrabroad antiviral activity spectrum of NV387 includes act... Lire le communiqué |
|
| |
|
| |
|
|
NV387 Possesses Strong AntiInfluenzaA Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. NYSE American:NNVC the "Company", a global leader in broadspectrum antiviral nanomedicines, says that the ultrabroad antiviral activity spectrum of NV387 includes Infl... Lire le communiqué |
|
| |
|
| |
|
|
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. NYSE Amer:NNVC the "Company", a global leader in broadspectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV387 is completed successfully and data lock is expected soon.The Phase 1 clinical trial, protocol number KMNVCoV2001, which received approval from the regulatory agency in India for healthy as... Lire le communiqué |
|
| |
|
| |
|
|
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. NYSE American:NNVC the "Company", a global leader in broadspectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10Q for the fiscal second quarter ending December 31, 2023 with the Securities and Exchange Commission SEC on Wednesday, February 14, 2024. The report can be accessed at the... Lire le communiqué |
|
| |
|
| |
|
|
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. NYSE American:NNVC the "Company", a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NVCoV2 oral drug products has implications beyond COVID, setting the Company up for long term success and... Lire le communiqué |
|
| |
|
| |
|
